Monoclonal antibody to cd man and its use

 

The invention relates to the field of immunobiotechnology and medicine and relates to monoclonal antibodies (MCAT) to SD person. MCAT includes antigennegative segment, specifically communicating with SD man, and a constant segment1 or3 person. This antigennegative segment selected from antibodies of a Primate, rodent, and gumanitarnogo antibodies or it is a derivative of MCAT EV, 6G5 or S. It is shown that MCAT suppresses IgE production in vitro and the expression of its in vivo by suppressing expression In cells. MCAT has a binding affinity of between 0.01-1000 nm, in particular at the level of 5 nm and 100 nm, and is also able to inhibit the binding of MCAT E, 6G5 or S to SD person with SD person. Described pharmaceutical composition based on MCAT for the treatment or prevention of a pathological state in which the suppression of IgE is therapeutically or prophylactically desirable, as well as a method of treatment or prevention using this antibody. The invention provides the possibility of targeted regulation of production or operation of IgE in vitro and in vivo. 3 S. and 17 C.p. f-crystals, 10 ill.

The text description to human CD23, including antigennegative segment, which specifically binds to CD23 man, and a constant segment1 person3 person.

2. The antibody under item 1, characterized in that it includes antigennegative segment of a Primate.

3. The antibody under item 1, characterized in that it includes antigennegative segment of the rodent.

4. The antibody under item 1, characterized in that it has humanitarian antigennegative part.

5. The antibody under item 1, characterized in that it inhibits the production of IgE in vitro.

6. The antibody under item 5, characterized in that it inhibits the expression of IgE by b-cells in vitro.

7. The antibody under item 1, characterized in that it inhibits the expression of IgE in vivo.

8. The antibody under item 1, characterized in that it has a binding affinity of between 0.01 to 1000 nm.

9. The antibody under item 1, characterized in that it has affinity binding to CD23 on the level of at least 5 nm.

10. The antibody under item 1, characterized in that it has a binding affinity of at the level of at least 100 nm.

11. The antibody under item 1, characterized in that antigennegative segment is derived E, 6G5 or S.

12. The antibody under item 1, characterized in that it is able to inhibit the binding of mono is really be able to inhibit the binding of monoclonal antibodies E to CD23 person with human CD23.

14. The antibody under item 1, characterized in that it is a monoclonal antibody1 man.

15. The antibody under item 1, characterized in that it is a monoclonal antibody3 person.

16. Pharmaceutical composition for treatment or prevention of a pathological state in which the suppression of IgE is therapeutically or prophylactically desirable, containing an effective amount of the antibody according to any one of paragraphs.1-10 and a pharmaceutically acceptable carrier.

17. Method for the treatment or prevention of a pathological state in which the suppression of IgE is therapeutically or prophylactically desirable, including the introduction of an effective amount of the antibody according to any one of paragraphs.1-7 or 11.

18. The method according to p. 17, wherein the disease state is an allergic disorder.

19. The method according to p. 17, characterized in that painful condition is an autoimmune disease.

20. The method according to p. 17, wherein the disease state is an inflammatory disease.

Priorities on items and features: 20.02.1997 on PP. 1-14, 16-20 (excluding the sign "const segment3"; 05.02.1998 on PP.1-20.

 

Same patents:

v-integrins (options), receive (options) and use hybridoma, polypeptide, dna" target="_blank">

The invention relates to immunobiotechnology and applies to new monoclonal antibodies, methods for their production using hybridoma technology and our-integrin or vitronectin as antigens, polypeptides, representing light and heavy chains of the antibody and DNA encoding these polypeptides

The invention relates to medicine, in particular for the diagnosis of metabolic bone diseases

The invention relates to medical biotechnology and is concerned with the obtaining of monoclonal antibodies (MAB) and its fragments using hybridoma FERM BR-4382, which produces the above-mentioned antibody

The invention relates to the field of veterinary Virology, in particular to a method for the diagnosis of sheep pox and goat
The invention relates to immunology and medicine and can be used for immunotherapy of malignant tumors

The invention relates to biotechnology, in particular to antibodies against Rtln, obtained by genetic engineering methods

The invention relates to the field of biotechnology and medicine, specifically to the diagnosis of opisthorchiasis

The invention relates to veterinary Virology, in particular to a method for the diagnosis of sheep pox and goat pox

The invention relates to veterinary Virology and biotechnology
The invention relates to medicine, namely to therapy, and for the treatment of cough

v-integrins (options), receive (options) and use hybridoma, polypeptide, dna" target="_blank">

The invention relates to immunobiotechnology and applies to new monoclonal antibodies, methods for their production using hybridoma technology and our-integrin or vitronectin as antigens, polypeptides, representing light and heavy chains of the antibody and DNA encoding these polypeptides

The invention relates to the field of biotechnology and medicine, namely preparations for the treatment of diseases of the cardiovascular system and methods of use thereof, in particular antithrombotic drugs based on monoclonal antibodies
The invention relates to medicine and can be used for the treatment and prevention of acute and chronic diseases associated with disruption of the blood, mainly granulocytopoiesis
The invention relates to medicine and can be used to obtain medicines without side effects, and treatment of various diseases associated with impaired immune response
The invention relates to medicine, namely to Oncology, and can be used for vaccine therapy of solid tumors

The invention relates to medicine

The invention relates to medicine

FIELD: genetic engineering, immunology, medicine.

SUBSTANCE: invention relates to new antibodies directed against antigenic complex CD3 and can be used in therapeutic aims. Antibody IgG elicits the affinity binding with respect to antigenic complex CD3 wherein heavy chain comprises skeleton of the human variable region in common with at least one CD3 taken among amino acid sequences SEQ ID NO 2, 4 and 6 and their corresponding conservatively modified variants. Light chain comprises skeleton of the rodent variable region in common with at least one CD3 taken among amino acid sequences SEQ ID NO 8, 10 and 12 and their corresponding conservatively modified variants. Antibody is prepared by culturing procaryotic or eucaryotic cell co-transformed with vector comprising recombinant nucleic acid that encodes antibody light chain and vector comprising recombinant nucleic acid that encodes antibody heavy chain. Antibody is administrated in the patient suffering with malignant tumor or needing in immunosuppression in the effective dose. Invention provides preparing chimeric antibodies against CD3 that are produced by expression systems of procaryotic and eucaryotic cells with the enhanced yield.

EFFECT: improved preparing methods, valuable medicinal properties of antibody.

33 cl, 5 dwg, 1 ex

Up!